These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21543938)

  • 1. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.
    Ledermann JA; Marth C; Carey MS; Birrer M; Bowtell DD; Kaye S; McNeish I; Oza A; Scambia G; Rustin G; Stehman FB; Gershenson D; Thomas G; Berns E; Casado A; Ottevanger N; Hilpert F; Kim BG; Okamoto A; Bacon M; Kitchener H; Stuart GC;
    Int J Gynecol Cancer; 2011 May; 21(4):763-70. PubMed ID: 21543938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials and future potential of targeted therapy for ovarian cancer.
    Itamochi H; Kigawa J
    Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line therapy in ovarian cancer trials.
    Thigpen T; duBois A; McAlpine J; DiSaia P; Fujiwara K; Hoskins W; Kristensen G; Mannel R; Markman M; Pfisterer J; Quinn M; Reed N; Swart AM; Berek J; Colombo N; Freyer G; Gallardo D; Plante M; Poveda A; Rubinstein L; Bacon M; Kitchener H; Stuart GC;
    Int J Gynecol Cancer; 2011 May; 21(4):756-62. PubMed ID: 21543937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in ovarian cancer.
    Lim HJ; Ledger W
    Womens Health (Lond); 2016 Jun; 12(3):363-78. PubMed ID: 27215391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents in epithelial ovarian cancer.
    See HT; Kavanagh JJ
    Cancer Invest; 2004; 22 Suppl 2():29-44. PubMed ID: 15573743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment and clinical trials in ovarian cancer.
    Han LY; Kipps E; Kaye SB
    Expert Opin Investig Drugs; 2010 Apr; 19(4):521-34. PubMed ID: 20367193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Anticancer Drugs; 2020 Feb; 31(2):101-109. PubMed ID: 31743133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    Chartron E; Theillet C; Guiu S; Jacot W
    Crit Rev Oncol Hematol; 2019 Jan; 133():58-73. PubMed ID: 30661659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs in ovarian cancer.
    Fleming GF
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical trials in recurrent ovarian cancer.
    Friedlander M; Trimble E; Tinker A; Alberts D; Avall-Lundqvist E; Brady M; Harter P; Pignata S; Pujade-Lauraine E; Sehouli J; Vergote I; Beale P; Bekkers R; Calvert P; Copeland L; Glasspool R; Gonzalez-Martin A; Katsaros D; Kim JW; Miller B; Provencher D; Rubinstein L; Atri M; Zeimet A; Bacon M; Kitchener H; Stuart GC;
    Int J Gynecol Cancer; 2011 May; 21(4):771-5. PubMed ID: 21543939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies for treatment of recurrent ovarian cancer.
    Grisham RN; Hyman DM; Iyer G
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of targeted therapy in ovarian cancer.
    Banerjee S; Kaye S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMPs in ovarian cancer as therapeutic targets.
    Karam A; Dorigo O
    Anticancer Agents Med Chem; 2012 Sep; 12(7):764-72. PubMed ID: 22292752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.
    Weberpals JI; Koti M; Squire JA
    Cancer Genet; 2011 Oct; 204(10):525-35. PubMed ID: 22137482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
    Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
    Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatments for ovarian cancer.
    Muggia F; Lu MJ
    Expert Opin Emerg Drugs; 2003 May; 8(1):203-16. PubMed ID: 14610922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.
    Hollebecque A; Massard C; Soria JC
    Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted agents in ovarian cancer.
    Kristedja TS; Morgan RJ; Cristea M
    Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy.
    Gong H; Nie D; Li Z
    Curr Cancer Drug Targets; 2020; 20(11):853-867. PubMed ID: 32807056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.